Gilbert D. Padula

Dr. Gilbert D. Padula

Radiation Oncology
Mercy Health — Boardman Medical Oncology
8401 Market Street, 
Boardman, OH 
Accepting New Patients
Referral may be required
Before you request
Mercy Health — Boardman Medical Oncology
8401 Market Street, 
Boardman, OH 

Overview

Gilbert Padula is a Radiation Oncologist practicing medicine in Boardman, Ohio.

His clinical expertise encompasses Breast Cancer, Throat Cancer, Laryngeal Cancer, and Lung Cancer.

Dr. Padula is board certified in American Board Of Radiology. He is actively involved in clinical research, co-authoring 16 peer reviewed articles and participating in 9 clinical trials. Dr. Padula is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in MI

Board Certifications

American Board Of Radiology

Hospital Affiliations

Mh St Elizabeth Youngstown Hospital
Mercy Health - St. Joseph Warren Hospital
Mercy Health - St. Elizabeth Youngstown Hospital
Mercy Health - St. Elizabeth Boardman Hospital

Languages Spoken

English
Italian

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
SummaCare
  • HMO
  • PPO
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Mercy Health — Boardman Medical Oncology
8401 Market Street, Boardman, OH 44512
Other Locations
Mercy Health — St. Elizabeth Youngstown Radiation Oncology
1044 Belmont Avenue, Youngstown, OH 44504

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2026
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: August 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women With Early Stage Breast Cancer
Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women With Early Stage Breast Cancer
Enrollment Status: Completed
Publish Date: December 07, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

16 Total Publications

Exploratory Analysis of Associations Between Whole Blood Mitochondrial Gene Expression and Cancer-Related Fatigue Among Breast Cancer Survivors.
Exploratory Analysis of Associations Between Whole Blood Mitochondrial Gene Expression and Cancer-Related Fatigue Among Breast Cancer Survivors.
Journal: Nursing research
Published: April 13, 2022
Similar Doctors
Expertise in
31
conditions
Dr. Michael A. Weller
Radiation Oncology
Expertise in
31
conditions
Dr. Michael A. Weller
Radiation Oncology
Referral may be required

Hillcrest Hospital

6780 Mayfield Rd, 
Mayfield Heights, OH 
 (54.2 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Weller is a Radiation Oncologist practicing medicine in Mayfield Heights, Ohio. Dr. Weller is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Thrombectomy, and Gamma Knife Radiosurgery.

Expertise in
51
conditions
Dr. Samuel T. Chao
Radiation Oncology
Expertise in
51
conditions
Dr. Samuel T. Chao
Radiation Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

9500 Euclid Ave, 
Cleveland, OH 
 (61.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Samuel Chao is a Radiation Oncologist practicing medicine in Cleveland, Ohio. Dr. Chao is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioma, Astrocytoma, Glioblastoma, and Gamma Knife Radiosurgery. Dr. Chao is board certified in American Board Of Radiology, 2007. Dr. Chao is currently accepting new patients.

Expertise in
17
conditions
Dr. Sushil Beriwal
Radiation Oncology
Expertise in
17
conditions
Dr. Sushil Beriwal
Radiation Oncology
Referral may be required

West Penn Hosp Outpatient SVCS Allegheny

314 E North Ave, 
Pittsburgh, PA 
 (50.6 miles away)
412-359-3400
Languages Spoken:
English
See accepted insurances

Sushil Beriwal is a Radiation Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Beriwal is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Vaginal Cancer, Vulvar Cancer, Cervical Cancer, Vulvectomy, and Orchiectomy.

Frequently Asked Questions about Dr. Gilbert D. Padula

How do I make an appointment with Dr. Gilbert D. Padula?

You can book an appointment with Dr. Gilbert D. Padula by calling their office at 330-729-7530. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gilbert D. Padula a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gilbert D. Padula is classified as an Experienced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gilbert D. Padula specialize in?

While Dr. Gilbert D. Padula is a Radiation Oncology, they have specific expertise in Breast Cancer, Throat Cancer, and Laryngeal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Gilbert D. Padula participate in research or clinical trials?

Yes. Dr. Gilbert D. Padula has published 16 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Gilbert D. Padula's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gilbert D. Padula accept my insurance?

Dr. Gilbert D. Padula accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 330-729-7530 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Padula's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile